Form 8-K - Current report:
SEC Accession No. 0001140361-24-015318
Filing Date
2024-03-26
Accepted
2024-03-26 17:03:08
Documents
13
Period of Report
2024-03-22
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K ef20025179_8k.htm   iXBRL 8-K 26131
  Complete submission text file 0001140361-24-015318.txt   162721

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA gyre-20240322.xsd EX-101.SCH 3907
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20240322_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20240322_pre.xml EX-101.PRE 16072
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20025179_8k_htm.xml XML 4205
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 24784519
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)